ZENTIVA PHARMA UK LIMITED
Get an alert when ZENTIVA PHARMA UK LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
—
Latest balance sheet
Net assets
£7.6M
-9.5% lowest in 3 filed years
Employees
51
-1.9% vs 2024
Profit before tax
£753K
+202% highest in 3 filed years
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
1 PSC ceased in last 24 months
Significant control changed hands — see the Ownership section.
Net assets
3-year trend · vs Consumer Discretionary median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £111,862,000 | £123,456,000 | £119,349,000 | -3.3% | |
| Operating profit | £2,327,000 | £3,084,000 | £2,801,000 | -9.2% | |
| Profit before tax | -£1,057,000 | -£738,000 | £753,000 | +202% | |
| Net profit | -£2,122,000 | -£2,187,000 | -£791,000 | +63.8% | |
| Cash | £20,033,000 | — | — | — | |
| Total assets less current liabilities | £49,480,000 | £45,290,000 | £45,217,000 | -0.2% | |
| Net assets | £10,534,000 | £8,347,000 | £7,556,000 | -9.5% | |
| Equity | £10,534,000 | £8,347,000 | £7,556,000 | -9.5% | |
| Average employees | 49 | 52 | 51 | -1.9% | |
| Wages | £4,445,000 | £4,587,000 | £5,956,000 | +29.8% | |
| Directors' remuneration | £432,000 | £410,000 | £512,000 | +24.9% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Operating margin | 2.1% | 2.5% | 2.3% | |
| Net margin | -1.9% | -1.8% | -0.7% | |
| Return on capital employed | 4.7% | 6.8% | 6.2% | |
| Gearing (liabilities / total assets) | 87.9% | 91.1% | 91.8% | |
| Current ratio | 1.95x | 1.71x | 1.80x | |
| Interest cover | 0.54x | 0.50x | 0.65x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 5 times since incorporation
- ZENTIVA PHARMA UK LIMITED 2018-07-05 → present
- WINTHROP PHARMACEUTICALS UK LIMITED 2004-12-30 → 2018-07-05
- STERWIN MEDICINES LIMITED 2000-11-01 → 2004-12-30
- SANOFI-SYNTHELABO LIMITED 1999-08-16 → 2000-11-01
- SANOFI PHARMA LTD 1988-05-04 → 1999-08-16
- OPENHEATH LIMITED 1987-08-28 → 1988-05-04
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Abridged
- Yes — abridged accounts (limited disclosure)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“A support letter from the Company's parent company has been obtained confirming that it has the ability to and will provide financial support to the Company for at least the period to 30 June 2027, being the going concern review period assessed by the directors. The directors continue to adopt the going concern basis in preparing the annual report and financial statements.”
Significant events
- “The company took the decision to consolidate operations out of its Guildford office and began the process of closing the Felsted site.”
- “On 17 April 2026, the Company signed an agreement with Al Sirona (Luxembourg) Acquisition S.a.r.l., in which it was agreed that the long term debt receivable by the Company from Al Sirona, would be offset against the long term debt payable by the Company to Al Sirona. The balances were thereby agreed to be settled with the effective date of 31 March 2026. The difference between the two debt amounts was agreed to be set against the short term debt receivable by the Company from Al Sirona.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 27 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BANERJEE, Siddharth | Director | 2026-06-03 | Jun 1990 | Indian |
| QUIN, Sophie | Director | 2022-08-09 | Feb 1980 | British |
Show 27 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| MCCLELLAN, Michael James | Secretary | 2008-02-13 | 2010-05-12 |
| ROBERTS, Helen | Secretary | 2001-01-02 | 2008-01-30 |
| THUILLIEZ, Gordon Dennis | Secretary | 1996-06-30 | 2000-01-02 |
| WARNOCK-SMITH, Anthony | Secretary | — | 1996-06-30 |
| BEWS, Susan Mary Maud, Dr | Director | — | 1998-12-24 |
| BROOKSBY, Nigel Stanley | Director | 1996-06-30 | 2010-05-12 |
| DARK, Blake Alexander Richard | Director | 2005-02-28 | 2007-11-16 |
| DE FORCEVILLE, Guillaume Adrien | Director | 2004-11-08 | 2007-11-16 |
| DUHALDE, Francois-Xavier | Director | 2016-04-01 | 2018-09-21 |
| FRY, Hugo Rupert Alexander | Director | 2017-01-01 | 2018-09-21 |
| GOURLET, Christophe | Director | 2001-01-02 | 2003-04-01 |
| HART, Luke Ingmire | Director | 2019-07-15 | 2023-01-22 |
| HILL, Jane | Director | 2019-02-01 | 2020-11-30 |
| JACOB, Etienne Marie Charles Robert | Director | 2004-11-08 | 2006-12-31 |
| KHANDELWAL, Manish | Director | 2018-09-21 | 2019-09-02 |
| KING, Eric | Director | 2001-01-02 | 2005-02-28 |
| KNIGHT, Anthony Daniel | Director | 2020-09-09 | 2026-05-31 |
| MCCLELLAN, Michael James | Director | 2007-11-16 | 2010-10-01 |
| OLDFIELD, Stephen Philip | Director | 2010-05-12 | 2014-07-25 |
| PROSSER, Andrew Michael James | Director | 2010-09-01 | 2016-04-01 |
| SELL, Piret | Director | 2018-09-21 | 2019-02-01 |
| STENVALL, Tarja Johanna | Director | 2014-11-19 | 2016-09-30 |
| THIBERGE, Olivier Alain | Director | 2001-01-02 | 2002-10-31 |
| THUILLIEZ, Gordon Dennis | Director | 1998-12-24 | 2000-01-02 |
| VERNIER, Thierry | Director | 2003-04-01 | 2004-11-08 |
| WARNOCK-SMITH, Anthony | Director | — | 1996-06-30 |
| WODDIS, Paul | Director | — | 1994-06-28 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Ai Sirona (Luxembourg ) Limited | Corporate entity | Shares 75–100% | 2019-09-01 | Ceased 2026-04-08 |
| Ai Sirona (Luxembourg ) Limited | Corporate entity | Shares 75–100% | 2019-09-01 | Ceased 2019-09-01 |
| Ai Sirona (Luxembourg) Acquisition S.A.R.L. | Corporate entity | Shares 75–100% | 2018-09-30 | Ceased 2018-09-30 |
| Aventis Pharma Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2018-09-30 |
Filing timeline
Last 20 of 208 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-06-19 | AA | accounts | Accounts with accounts type full | |
| 2026-06-05 | AP01 | officers | Appoint person director company with name date | |
| 2026-06-01 | TM01 | officers | Termination director company with name termination date | |
| 2026-05-22 | PSC08 | persons-with-significant-control | Notification of a person with significant control statement | |
| 2026-05-22 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2026-01-07 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-01-07 | AD02 | address | Change sail address company with old address new address | |
| 2025-07-14 | AA | accounts | Accounts with accounts type full | |
| 2025-01-31 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-25 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2024-10-16 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2024-09-11 | AA | accounts | Accounts with accounts type full | |
| 2024-07-16 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2024-02-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-11-07 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2023-08-25 | AA | accounts | Accounts with accounts type full | |
| 2023-01-31 | TM01 | officers | Termination director company with name termination date | |
| 2023-01-13 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-08-23 | AP01 | officers | Appoint person director company with name date | |
| 2022-06-27 | AA | accounts | Accounts with accounts type full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 8
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.